Published on October 21, 2009 at 5:51 AM
Medivir (STO:MVIRB)
• Consolidated net sales were SEK 24.5 (31.9) m.
• The loss after tax was SEK -93.0 (-102.4) m.
• Earnings per share were SEK -4.46 (-4.91).
• Cash flow from operating activities was SEK -104.8 (-30.4) m.
• Liquid assets and short-term investments as of 30 September were SEK 176.1 (295.7) m.
Third quarter in brief
Several significant project events were reported in the quarter.
The highlights can be summarized as follows:
• FDA approved Lipsovir® with a competitive label for marketing and sales in the US.
• At present, two phase IIb trials involving a total of 855 patients are ongoing on TMC435 against hepatitis C. The latter of these trials (C-206) started in September and involves 455 patients that previously did not respond to standard of care (SoC).
• Medivir designated another candidate drug (CD), MIV-711 in its osteoporosis portfolio, thus enhancing its commercial opportunities.
Ron Long
CEO
Huddinge, Sweden, 21 October 2009
FORTHCOMING FINANCIAL INFORMATION
The Financial Statement for 12 months will be published on 18 February 2010.
The Three-month Interim Report will be published on 29 April 2010.
The Annual General Meeting (AGM) will be held on 29 April 2010.
The Reports will be available at Medivir’s Website, www.medivir.se from this date under the ‘Investor/Media’ heading.
http://www.cisionwire.com